The biopharma companies are restructuring the programs to reposition the companies under the clinical science and well-funded category. The companies are refocusing on R&D, downsizing the manufacturing facilities, and integrating technologies to automate the workflow. Despite a sluggish start, the biosimilar market looks set for accelerated growth. The patient co-pay dynamic, financial incentives and commercial model will be the factors driving the growth of the industry. Amid breakthroughs in biosimilars, gene editing, and the reconsideration of development and reimbursement models for the therapies have revolutionized the traditional approach for disease treatments by pharmaceuticals.